Casgevy; Overview On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two groundbreaking gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease (SCD) in patients aged 12 and older. These approvals mark significant advancements in the field of gene therapy, with Casgevy being particularly notable as it is the … Continue reading Casgevy – CRISPR-Based Therapy for Sickle Cell Disease